Cargando…
The Hasford Score May Predict Molecular Response in Chronic Myeloid Leukemia Patients: A Single Institution Experience
The Sokal, Hasford, and EUTOS scores were established in different treatment eras of chronic myeloid leukemia (CML). None of them was reported to predict molecular response. In this single center study we tried to reevaluate the usefulness of three main scores in TKI era. The study group included 88...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5080519/ https://www.ncbi.nlm.nih.gov/pubmed/27818567 http://dx.doi.org/10.1155/2016/7531472 |
_version_ | 1782462735536095232 |
---|---|
author | Dybko, Jarosław Jaźwiec, Bożena Haus, Olga Urbaniak-Kujda, Donata Kapelko-Słowik, Katarzyna Wróbel, Tomasz Lonc, Tomasz Sawicki, Mateusz Mędraś, Ewa Kaczmar-Dybko, Agnieszka Kuliczkowski, Kazimierz |
author_facet | Dybko, Jarosław Jaźwiec, Bożena Haus, Olga Urbaniak-Kujda, Donata Kapelko-Słowik, Katarzyna Wróbel, Tomasz Lonc, Tomasz Sawicki, Mateusz Mędraś, Ewa Kaczmar-Dybko, Agnieszka Kuliczkowski, Kazimierz |
author_sort | Dybko, Jarosław |
collection | PubMed |
description | The Sokal, Hasford, and EUTOS scores were established in different treatment eras of chronic myeloid leukemia (CML). None of them was reported to predict molecular response. In this single center study we tried to reevaluate the usefulness of three main scores in TKI era. The study group included 88 CML patients in first chronic phase treated initially with standard imatinib dose. All of them achieved major molecular response (MMR) in time points defined by European LeukemiaNet (ELN). 42 patients lost MMR in a median time of 47 months and we found a significant difference in MMR maintenance between intermediate-risk (IR) and low-risk (LR) patients assessed by Hasford score. All 42 patients were switched to second-generation TKI (2G-TKI) treatment. At 18 months of 2G-TKI therapy we have still found a significant difference in BCR-ABL transcript levels and MMR rate between IR and LR groups. We did not find any of the described differences discriminating patients by Sokal or EUTOS score. In this retrospective single center analysis we found Hasford score to be useful in predicting molecular response in first chronic phase of CML patients. |
format | Online Article Text |
id | pubmed-5080519 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-50805192016-11-06 The Hasford Score May Predict Molecular Response in Chronic Myeloid Leukemia Patients: A Single Institution Experience Dybko, Jarosław Jaźwiec, Bożena Haus, Olga Urbaniak-Kujda, Donata Kapelko-Słowik, Katarzyna Wróbel, Tomasz Lonc, Tomasz Sawicki, Mateusz Mędraś, Ewa Kaczmar-Dybko, Agnieszka Kuliczkowski, Kazimierz Dis Markers Research Article The Sokal, Hasford, and EUTOS scores were established in different treatment eras of chronic myeloid leukemia (CML). None of them was reported to predict molecular response. In this single center study we tried to reevaluate the usefulness of three main scores in TKI era. The study group included 88 CML patients in first chronic phase treated initially with standard imatinib dose. All of them achieved major molecular response (MMR) in time points defined by European LeukemiaNet (ELN). 42 patients lost MMR in a median time of 47 months and we found a significant difference in MMR maintenance between intermediate-risk (IR) and low-risk (LR) patients assessed by Hasford score. All 42 patients were switched to second-generation TKI (2G-TKI) treatment. At 18 months of 2G-TKI therapy we have still found a significant difference in BCR-ABL transcript levels and MMR rate between IR and LR groups. We did not find any of the described differences discriminating patients by Sokal or EUTOS score. In this retrospective single center analysis we found Hasford score to be useful in predicting molecular response in first chronic phase of CML patients. Hindawi Publishing Corporation 2016 2016-10-12 /pmc/articles/PMC5080519/ /pubmed/27818567 http://dx.doi.org/10.1155/2016/7531472 Text en Copyright © 2016 Jarosław Dybko et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Dybko, Jarosław Jaźwiec, Bożena Haus, Olga Urbaniak-Kujda, Donata Kapelko-Słowik, Katarzyna Wróbel, Tomasz Lonc, Tomasz Sawicki, Mateusz Mędraś, Ewa Kaczmar-Dybko, Agnieszka Kuliczkowski, Kazimierz The Hasford Score May Predict Molecular Response in Chronic Myeloid Leukemia Patients: A Single Institution Experience |
title | The Hasford Score May Predict Molecular Response in Chronic Myeloid Leukemia Patients: A Single Institution Experience |
title_full | The Hasford Score May Predict Molecular Response in Chronic Myeloid Leukemia Patients: A Single Institution Experience |
title_fullStr | The Hasford Score May Predict Molecular Response in Chronic Myeloid Leukemia Patients: A Single Institution Experience |
title_full_unstemmed | The Hasford Score May Predict Molecular Response in Chronic Myeloid Leukemia Patients: A Single Institution Experience |
title_short | The Hasford Score May Predict Molecular Response in Chronic Myeloid Leukemia Patients: A Single Institution Experience |
title_sort | hasford score may predict molecular response in chronic myeloid leukemia patients: a single institution experience |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5080519/ https://www.ncbi.nlm.nih.gov/pubmed/27818567 http://dx.doi.org/10.1155/2016/7531472 |
work_keys_str_mv | AT dybkojarosław thehasfordscoremaypredictmolecularresponseinchronicmyeloidleukemiapatientsasingleinstitutionexperience AT jazwiecbozena thehasfordscoremaypredictmolecularresponseinchronicmyeloidleukemiapatientsasingleinstitutionexperience AT hausolga thehasfordscoremaypredictmolecularresponseinchronicmyeloidleukemiapatientsasingleinstitutionexperience AT urbaniakkujdadonata thehasfordscoremaypredictmolecularresponseinchronicmyeloidleukemiapatientsasingleinstitutionexperience AT kapelkosłowikkatarzyna thehasfordscoremaypredictmolecularresponseinchronicmyeloidleukemiapatientsasingleinstitutionexperience AT wrobeltomasz thehasfordscoremaypredictmolecularresponseinchronicmyeloidleukemiapatientsasingleinstitutionexperience AT lonctomasz thehasfordscoremaypredictmolecularresponseinchronicmyeloidleukemiapatientsasingleinstitutionexperience AT sawickimateusz thehasfordscoremaypredictmolecularresponseinchronicmyeloidleukemiapatientsasingleinstitutionexperience AT medrasewa thehasfordscoremaypredictmolecularresponseinchronicmyeloidleukemiapatientsasingleinstitutionexperience AT kaczmardybkoagnieszka thehasfordscoremaypredictmolecularresponseinchronicmyeloidleukemiapatientsasingleinstitutionexperience AT kuliczkowskikazimierz thehasfordscoremaypredictmolecularresponseinchronicmyeloidleukemiapatientsasingleinstitutionexperience AT dybkojarosław hasfordscoremaypredictmolecularresponseinchronicmyeloidleukemiapatientsasingleinstitutionexperience AT jazwiecbozena hasfordscoremaypredictmolecularresponseinchronicmyeloidleukemiapatientsasingleinstitutionexperience AT hausolga hasfordscoremaypredictmolecularresponseinchronicmyeloidleukemiapatientsasingleinstitutionexperience AT urbaniakkujdadonata hasfordscoremaypredictmolecularresponseinchronicmyeloidleukemiapatientsasingleinstitutionexperience AT kapelkosłowikkatarzyna hasfordscoremaypredictmolecularresponseinchronicmyeloidleukemiapatientsasingleinstitutionexperience AT wrobeltomasz hasfordscoremaypredictmolecularresponseinchronicmyeloidleukemiapatientsasingleinstitutionexperience AT lonctomasz hasfordscoremaypredictmolecularresponseinchronicmyeloidleukemiapatientsasingleinstitutionexperience AT sawickimateusz hasfordscoremaypredictmolecularresponseinchronicmyeloidleukemiapatientsasingleinstitutionexperience AT medrasewa hasfordscoremaypredictmolecularresponseinchronicmyeloidleukemiapatientsasingleinstitutionexperience AT kaczmardybkoagnieszka hasfordscoremaypredictmolecularresponseinchronicmyeloidleukemiapatientsasingleinstitutionexperience AT kuliczkowskikazimierz hasfordscoremaypredictmolecularresponseinchronicmyeloidleukemiapatientsasingleinstitutionexperience |